Stocktoria
vTv Therapeutics Inc. VTVT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-07-30
Chart by TradingView
3/9
Piotroski F — financial health
-5.57
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $0 | $1.0M | $0 | $2.0M | $4.0M |
| Operating income | -$32.8M | -$24.2M | -$25.5M | -$22.5M | -$21.7M |
| Net income | -$27.0M | -$18.5M | -$20.2M | -$19.2M | -$13.0M |
| Operating cash flow | -$25.3M | -$25.3M | -$19.1M | -$16.0M | -$19.3M |
| Free cash flow | — | -$25.3M | -$19.1M | -$16.0M | -$19.3M |
| Total assets | $89.9M | $38.3M | $11.0M | $33.2M | $25.5M |
| Total liabilities | $25.5M | $24.0M | $29.6M | $27.4M | $10.3M |
| Shareholders' equity | $64.4M | $14.3M | -$24.7M | -$10.7M | -$9.7M |
| Ratios | |||||
| Operating margin | — | -2377.6% | — | -1116.9% | -540.9% |
| Net margin | — | -1815.3% | — | -949.7% | -324.3% |
| FCF margin | — | -2488.4% | — | -795.0% | -482.1% |
| Return on assets | -30.0% | -48.2% | -183.8% | -57.7% | -51.0% |
| Return on equity | -41.9% | -129.1% | 82.1% | 178.4% | 133.3% |
| Current ratio | 13.54 | 7.34 | 1.00 | 3.52 | 1.84 |
| Revenue growth | -100.0% | — | -100.0% | -49.6% | -37.6% |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -5.57 (distress)
- Working capital / assets 0.926
- Retained earnings / assets -3.634
- EBIT / assets -0.365
- Equity / liabilities 2.531
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001641489 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.